Janux Therapeutics Inc (NASDAQ: JANX) on Monday, plunged -9.40% from the previous trading day, before settling in for the closing price of $32.88. Within the past 52 weeks, JANX’s price has moved between $22.52 and $71.71.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 32.33% over the past five years. The company achieved an average annual earnings per share of -42.48%. With a float of $49.40 million, this company’s outstanding shares have now reached $59.06 million.
Let’s look at the performance matrix of the company that is accounted for 81 employees. In terms of profitability, gross margin is 90.2%, operating margin of -933.58%, and the pretax margin is -651.62%.
Janux Therapeutics Inc (JANX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Janux Therapeutics Inc is 16.42%, while institutional ownership is 108.13%. The most recent insider transaction that took place on May 01 ’25, was worth 106,745. In this transaction Chief Business Officer of this company sold 3,333 shares at a rate of $32.03, taking the stock ownership to the 82,139 shares. Before that another transaction happened on May 01 ’25, when Company’s Officer proposed sale 3,333 for $33.20, making the entire transaction worth $110,656.
Janux Therapeutics Inc (JANX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -42.48% per share during the next fiscal year.
Janux Therapeutics Inc (NASDAQ: JANX) Trading Performance Indicators
Janux Therapeutics Inc (JANX) is currently performing well based on its current performance indicators. A quick ratio of 59.21 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 166.44.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.28, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -2.28 in one year’s time.
Technical Analysis of Janux Therapeutics Inc (JANX)
Janux Therapeutics Inc (NASDAQ: JANX) saw its 5-day average volume 1.06 million, a positive change from its year-to-date volume of 0.97 million. As of the previous 9 days, the stock’s Stochastic %D was 51.23%. Additionally, its Average True Range was 1.99.
During the past 100 days, Janux Therapeutics Inc’s (JANX) raw stochastic average was set at 16.59%, which indicates a significant decrease from 30.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.28% in the past 14 days, which was lower than the 65.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $30.11, while its 200-day Moving Average is $43.15. Nevertheless, the first resistance level for the watch stands at $31.04 in the near term. At $32.30, the stock is likely to face the second major resistance level. The third major resistance level sits at $33.20. If the price goes on to break the first support level at $28.88, it is likely to go to the next support level at $27.98. Assuming the price breaks the second support level, the third support level stands at $26.72.
Janux Therapeutics Inc (NASDAQ: JANX) Key Stats
Market capitalization of the company is 1.76 billion based on 59,168K outstanding shares. Right now, sales total 10,590 K and income totals -68,990 K. The company made 440 K in profit during its latest quarter, and -28,060 K in sales during its previous quarter.
